"William Blair believes that Zimmer’s (NYSE:ZMH) iASSIST Knee is currently a threat to MAKO Surgical’s partial knee business. The firm thinks that it will take a number of years for Zimmer to develop the clinical data that is needed for surgeons to feel comfortable using the product. William Blair believes that MAKO will begin to start meeting or exceeding consensus expectations, and the firm reiterates its Outperform rating on the stock."
Does this make any sense? Seems like they're contradicting themselves.